Genmab — Marts 2020
-
Analyst Commentary
H.C. Wainwright - little impact https://twitter.com/Quantumup1/status/1244597967283261442 -
J&J 4% oppe på vaccinenyhed.
-
JNJ-61186372, EGFR +cMet increased trial size from 400 to 460 https://clinicaltrials.gov/ct2/history/NCT02609776?A=44&B=45&C=merged#StudyPageTop
-
Desværre ja.
-
-
Copenhagen, Denmark, March 30, 2020
Genmab filed Form 20-F for the financial year 2019 with the U.S. SEC
Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2019 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2019.
-
Google er din ven hspinvest. https://www.investopedia.com/terms/s/sec-form-20-f.asp
-
Så I røgen.
-
Nyheder fra TV204, dara subQ, Andromeda samt ofa MS må være på trapperne, da disse ikke kan være forsinkede af coronavirusen
-
epcoritamab data og partner aftale kan være forsinkede, ligesom de andre early stage studier...
-
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30070-3/fulltext#.XoLLnLG9fvA.twitter
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind